

PART III: CONSUMER INFORMATION

Pr MYLAN-VERAPAMIL SR
verapamil hydrochloride sustained-release tablet,
USP

This leaflet is PART III of a three-part "Product Monograph" published when MYLAN-VERAPAMIL SR was approved for sale in Canada and is designed specifically for consumers. This leaflet is a summary and will not tell you everything about MYLAN-VERAPAMIL SR. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION**What the medication is used for:**

- MYLAN-VERAPAMIL SR is used to treat hypertension (high blood pressure).

What it does:

MYLAN-VERAPAMIL SR is a calcium channel blocker. Calcium channel blockers change the amount of calcium getting into the muscle cells of your heart and blood vessels. This can change the strength and speed at which your heart beats. It also opens up the blood vessels so that blood can be pumped around your body more easily. This helps to lower your blood pressure.

When it should not be used:

MYLAN-VERAPAMIL SR should not be used if:

- you are allergic to any component of MYLAN-VERAPAMIL SR, including the active ingredient or the nonmedicinal ingredients. See (**What the nonmedicinal ingredients are**).
- you have certain serious heart disease or problems.
- you feel faint when you get up.
- you have symptoms such as rapid pulse and breathing, anxiety, weakness, decreased urine production, cool hands and feet and loss of alertness. See your doctor immediately.
- you have had a heart attack.
- you have slow heartbeat or irregular heartbeat.
- you are breast-feeding while taking this medication.
- you are taking ivabradine, a drug that lowers your heart rate.
- you are taking flibanserin, a medicine to treat generalized hypoactive sexual desire disorder. You must wait at least 2 weeks after your last dose of MYLAN-VERAPAMIL SR before starting flibanserin. You must wait at least 2 days after your last dose of flibanserin before starting MYLAN-VERAPAMIL SR.
Ask your doctor for advice.

What the medicinal ingredient is:

MYLAN-VERAPAMIL SR contains verapamil hydrochloride.

What the non-medicinal ingredients are:

povidone, sodium alginate, microcrystalline cellulose, magnesium stearate and sodium lauryl sulfate.

The 120 mg tablet white coating contains polyvinyl alcohol, titanium dioxide, macrogol and talc.

The 180 mg tablet pink coating contains polyvinyl alcohol, titanium dioxide, macrogol, talc and iron oxide red.

The 240 mg tablet green coating contains polyvinyl alcohol, titanium dioxide, macrogol, talc, D&C Yellow #10 Aluminum Lake, FD&C Blue #2 and iron oxide red.

What dosage forms it comes in:

MYLAN-VERAPAMIL SR is available as sustained-release tablets in the following strengths: 120 mg, 180 mg, 240 mg.

WARNINGS AND PRECAUTIONS**BEFORE you use MYLAN-VERAPAMIL SR talk to your doctor or pharmacist if:**

- you are pregnant or planning to become pregnant
- you have any heart disease.
- you have kidney disease.
- you have liver disease.
- you are taking beta-blockers. See (**Interactions With This Medication**).
- you have neuromuscular disease (i.e. myasthenia gravis or Duchenne muscular dystrophy).

INTERACTIONS WITH THIS MEDICATION**Drugs that may interact with MYLAN-VERAPAMIL****SR include:**

- beta-blockers (e.g. propranolol, metoprolol, atenolol, timolol);
- any other treatment for hypertension (high blood pressure) or an arrhythmia (abnormal heart beat) (e.g. hydrochlorothiazide, disopyramide, flecainide, quinidine, prazosin, terazosin);
- Dabigatran, , rivaroxaban, apixaban, and edoxaban (blood thinners)
- digoxin, digitoxin, cimetidine, lithium, rifampicin, theophylline, sulfonpyrazone, clarithromycin, erythromycin, telithromycin, glyburide, almotriptan, colchicine;
- carbamazepine, phenobarbital, phenytoin;
- any of the group of medicines known as major tranquilizers, or an antidepressant of the tricyclic group (e.g. imipramine);
- any of the group of medicines known as benzodiazepines or other anti-anxiety treatment (e.g. buspirone, midazolam);
- any of the group of medicines known as non-steroidal anti-inflammatory drugs (e.g. acetylsalicylic acid);

- anti-cancer medication (e.g. doxorubicin);
- some medication that can affect your immune system (e.g. cyclosporine, sirolimus, tacrolimus, everolimus);
- any neuromuscular blocking agent (e.g. atracurium);
- some anti-cholesterol products (e.g. simvastatin, atorvastatin, lovastatin);
- some HIV-antiviral medication (e.g. ritonavir);
- grapefruit juice;
- alcohol;
- St. John's Wort,
- ivabradine (a drug that lowers your heart rate).

PROPER USE OF THIS MEDICATION

Usual dose:

Always take your tablets exactly as your doctor has told you. The usual starting adult dose for MYLAN-VERAPAMIL SR is 180 to 240 mg per day, taken at the same time every day. Dosage is individualized and your doctor will adjust your dose as needed. The maximum dose to treat high blood pressure is 480 mg each day. This is usually taken as one MYLAN-VERAPAMIL SR 240 mg tablet in the morning and one in the evening, leaving a gap of about 12 hours between each dose.

Tablets should be taken with sufficient liquid, preferably with or shortly after meals. Do not crush or chew the tablets.

The MYLAN-VERAPAMIL SR 180 mg and 240 mg tablets are scored. Only the 240 mg tablets may be cut in half without damaging the modified release formulation.

Overdose:

If you or someone you know accidentally takes more than stated dose, contact your doctor immediately or go to the nearest hospital with the tablets.

In case of accidental drug overdose, contact a health care practitioner, hospital emergency department or regional poison control centre immediately, even if there are no symptoms. Tell your doctor or hospital how much was taken. Treat even small overdoses seriously.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If you forget to take one tablet, take another as soon as you remember, unless it is almost time for your next dose. If it is, do not take the missed tablet at all.

Never double-up on a missed dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Along with its needed effects, a medicine may cause some unwanted effects. These are referred to as "side effects". Although not all of these side effects may occur, if they do occur they may need medical attention.

The most common side effects with MYLAN-VERAPAMIL SR are constipation, dizziness and feeling sick (nausea). Other less common side effects may include headache and tiredness.

Check with your physician or pharmacist if you experience any unexpected effects, or are concerned by the above side effects.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and seek immediate emergency medical attention
		Only if severe	In all cases	
Common	Feeling dizzy and faint or your blood pressure is too low		√	
	Difficulty breathing		√	
	Swelling in the arms or legs		√	
Uncommon	Feeling an irregular heart beat		√	
	Rash or other skin irritation		√	
	Muscle weakness		√	

This is not a complete list of side effects. For any unexpected effects while taking Mylan-Verapamil SR contact your doctor or pharmacist.

HOW TO STORE IT

Keep MYLAN-VERAPAMIL SR and all other medicines out of reach and sight of children.

MYLAN-VERAPAMIL SR tablets should be stored at 15° to 30°C. Protect from moisture and light.

Do not take your tablets after the expiry date shown on the label.

It is important to keep the MYLAN-VERAPAMIL SR tablets in the original package.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document can be found at: www.mylan.ca.

The full Product Monograph prepared for health professionals can be obtained by contacting the sponsor, Mylan Pharmaceuticals ULC at: 1-844 596-9526

This leaflet was prepared by Mylan Pharmaceuticals ULC

Etobicoke, Ontario M8Z 2S6

Revised on: January 15, 2020



Mylan Pharmaceuticals ULC
Etobicoke, ON M8Z 2S6
1-844 596-9526
www.mylan.ca